|
December 14, 2001
STUDY IN AMERICAN JOURNAL OF GASTROENTEROLOGY SHOWS TAP PHARMACEUTICAL PRODUCTS' LANSOPRAZOLE RELIEVES HEARTBURN FASTER THAN OMEPRAZOLE IN PATIENTS WITH EROSIVE ESOPHAGITIS
December 6, 2001
TAP NAMES L. STEPHAN VINCZE ETHICS AND COMPLIANCE OFFICER
October 22, 2001
TAP PROMISES PREVACID® PATIENT SATISFACTION WITH LAUNCH OF LANDMARK MONEY-BACK GUARANTEE PROGRAM
September 14, 2001
TAP SUPPORTS DISASTER RELIEF EFFORTS
September 12, 2001
TAP RECEIVES FDA APPROVAL FOR NEW CEPHALOSPORIN ANTIBIOTIC SPECTRACEFTM (CEFDITOREN PIVOXIL)
September 10, 2001
LIGAND EARNS MILESTONE PAYMENT AS TAP DECLARES LGD2226 A CLINICAL CANDIDATE
June 25, 2001
LIGAND PHARMACEUTICALS AND TAP PHARMACEUTICAL PRODUCTS SIGN COLLABORATIVE RESEARCH AGREEMENT
May 30, 2001
UNIMED AND TAP JOIN FORCES TO CO-PROMOTE ANDROGEL®
May 20, 2001
PREVACID® (LANSOPRAZOLE) PACKET FOR ORAL SUSPENSION IS A SAFE AND EFFECTIVE ALTERNATIVE TO CAPSULES
April 27, 2001
TAP PHARMACEUTICAL PRODUCTS INC. TO BUILD HABITAT HOUSE IN NORTH CHICAGO
Spectracef® is licensed to Purdue Pharmaceutical Products L.P. by Meiji Seika Kaisha, Ltd.
|
